|
CELG's Net Income Growth by Quarter and Year
Celgene's Net Income results by quarter and year
Select the Comparisons :
|
|
Select the Ratio:
|
|
CELG Net Income (in millions $) |
FY 2019 |
FY 2018 |
FY 2017 |
FY 2016 |
IV Quarter |
December |
-
|
-2,973.00
|
-2,990.00
|
428.90
|
III Quarter |
September |
1,691.00
|
1,082.00
|
988.00
|
171.40
|
II Quarter |
June |
1,571.00
|
1,045.00
|
1,061.00
|
598.20
|
I Quarter |
March |
1,545.00
|
846.00
|
941.00
|
800.70
|
FY |
|
4,807.00
|
0.00
|
0.00
|
1,999.20
|
CELG Net Income third quarter 2019 Y/Y Growth Comment |
Celgene Corp reported Net Income rise of 56.28% year on year in the third quarter 2019, to $ 1,691.00 millions, this is lower than Celgene Corp's recent average Net Income surge of 134.8%.
Looking into third quarter 2019 results within Major Pharmaceutical Preparations industry 7 other companies have achieved higher Net Income growth. While Celgene Corp' s Net Income jump of 56.28% ranks overall at the positon no. 350 in the third quarter 2019.
|
CELG Net Income ( Y/Y Growth %) |
2019
|
2018 |
2017 |
2016 |
IV Quarter |
December |
- |
- |
- |
- |
III Quarter |
September |
56.28 % |
9.51 % |
476.43 % |
- |
II Quarter |
June |
50.33 % |
-1.51 % |
77.37 % |
67.94 % |
I Quarter |
March |
82.62 % |
-10.1 % |
17.52 % |
11.38 % |
FY |
|
- |
- |
- |
1.7585149169998E+18 % |
CELG Net Income (Quarter on Quarter Growth %) |
2019
|
2018 |
2017 |
2016 |
IV Quarter |
December |
- |
- |
- |
150.23 % |
III Quarter |
September |
7.64 % |
3.54 % |
-6.88 % |
-71.35 % |
II Quarter |
June |
1.68 % |
23.52 % |
12.75 % |
-25.29 % |
I Quarter |
March |
- |
- |
119.4 % |
- |
FY (Year on Year) |
|
- |
- |
- |
1.7585149169998E+18 % |
Net Income Y/Y Growth Statistics |
High |
Average |
Low |
2959.43 % |
134.8 % |
-100 % |
(Sep. 30, 2006) |
|
(Mar 31 2014) |
|
Net Income Y/Y Growth Statistics |
High |
Average |
Low |
2959.43 % |
134.8 % |
-100 % |
(Sep. 30, 2006) |
|
(Mar 31 2014) |
|
Net Income by Quarter for the Fiscal Years 2016, 2017, 2018, 2019 |
Celgene's Q/Q Net Income Growth
Net Income Q/Q Growth Statistics |
High |
Average |
Low |
488.02 % |
26.73 % |
-100 % |
(Dec. 31, 2005) |
|
(Mar 31 2014) |
CELG's III. Quarter Q/Q Net Income Comment |
Celgene Corp achieved in the III. Quarter 2019 below company average Net Income increase of 7.64% quarter on quarter, to $ 1,691.00 millions.
Although the III. Quarter 2019 CELG's Net Income quarter on quarter growth was beneath the regular , this was yet encouraging news, as the III. Quarter surge, outshines the 3.54% rise in the same quarter a year ago
Within Major Pharmaceutical Preparations industry 11 other companies have achieved higher Net Income quarter on quarter growth. While Celgene's Net Income growth quarter on quarter, overall rank is 1015. |
|
|
Net Income Q/Q Growth Statistics |
High |
Average |
Low |
488.02 % |
26.73 % |
-100 % |
(Dec. 31, 2005) |
|
(Mar 31 2014) |
CELG's III. Quarter Q/Q Net Income Comment |
Celgene Corp achieved in the III. Quarter 2019 below company average Net Income increase of 7.64% quarter on quarter, to $ 1,691.00 millions.
III. Quarter 2019 CELG's results appear to be paradoxical, even if lower than the ordinary increase of 26.73 %, yet it demonstrates absolute acceleration compare to the 3.54% in the III. Quarter 2018 Georgia Smith, a business insider based in London wrote.
Within Major Pharmaceutical Preparations industry 11 other companies have achieved higher Net Income quarter on quarter growth. While Celgene's Net Income growth quarter on quarter, overall rank is 1015. |
|
Celgene's 12 Months Net Income Growth Year on Year
Net Income TTM Growth |
12 Months Ending (Sep 30 2019) |
12 Months Ending (Jun 30 2019) |
12 Months Ending (Mar 31 2019) |
12 Months Ending (Dec 31 2018) |
12 Months Ending (Sep 30 2018) |
Cumulative Net Income 12 Months Ending |
$ 1,834.00 |
$ 1,225.00 |
$ 699.00 |
$ 0.00 |
$ -17.00 |
Y / Y Net Income Growth (TTM) |
- |
- |
- |
- |
- |
Year on Year Net Income Growth Overall
Ranking |
# |
# |
# |
# |
# |
Seqeuential Net Income Change (TTM) |
49.71 % |
75.25 % |
- |
- |
- |
Seq. Net Income Growth (TTM) Overall
Ranking |
# 374 |
# 181 |
# 0 |
# 0 |
# 694 |
Cumulative Net Income growth
Comment |
Celgene saw improvement in Net Income growth trend, posting cumulative 12 months Net Income growth of 56.28% year on year, to $ 1,834 millions if the fiscal year would have ended in Sep 30 2019. Celgene's trailing twelve months Net Income growth was higher than company's average 0% and higher than % growth in Jun 30 2019. And, Celgene realized the fastest Net Income growth, in Major Pharmaceutical Preparations industry. But sequential growth rate was less at 49.71 % from $1225 millions recorded in twelve months ending a quarter before Georgia Smith added on. Still it was evidence of strength, as the average Q/Q TTM gain stands at 31.76%. In the Sep 30 2019 period, Celgene had cumulative twelve months Net Income of $ 1,834 millions compare to net loss of $ -17 millions a year ago. Besides CELG has regained the prosperity, it is, as of now improving fast and recording better then usual Net Income gain, from the twelve months ending in the quarter before of 49.71 % from $1225 millions.
Celgene Corp achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. . |
Net Income TTM Q/Q Growth Statistics |
High |
Average |
Low |
2515.53 % |
31.76 % |
-1433.8 % |
|
|
|
|
|
Net Income TTM Y/Y Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
Net Income TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 15 |
Sector |
# 46 |
S&P 500 |
# 374 |
|
Cumulative Net Income growth
Comment |
Celgene saw improvement in Net Income growth trend, posting cumulative 12 months Net Income growth of 56.28% year on year, to $ 1,834 millions if the fiscal year would have ended in Sep 30 2019. Celgene's trailing twelve months Net Income growth was higher than company's average 0% and higher than % growth in Jun 30 2019. And, Celgene realized the fastest Net Income growth, in Major Pharmaceutical Preparations industry. But from the previous reporting period growth rate was slower at 49.71 % from $1225 millions reported in the period from Jun 30 2019 to Sep 30 2018 Georgia Smith continued. Still this was confirmation of strength, while the average sequential growth is at 31.76%. The progress was much stronger from the previous reporting period exhibited at 49.71 % jump from $1225 millions in twelve months ending a quarter before. In the Sep 30 2019 period, Celgene had cumulative twelve months Net Income of $ 1,834 millions compare to net loss of $ -17 millions a year ago. Besides Major Pharmaceutical Preparations company has regained the profitability, the company by this time is improving fast and showing better then usual Net Income gain, from the twelve months ending in the quarter Jun 30 2019 of 49.71 % from $1225 millions.
Celgene Corp achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. . |
Net Income TTM Q/Q Growth Statistics |
High |
Average |
Low |
2515.53 % |
31.76 % |
-1433.8 % |
|
|
|
Net Income TTM Y/Y Growth Statistics |
High |
Average |
Low |
0 % |
0 % |
0 % |
|
|
|
Net Income TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 15 |
Sector |
# 46 |
S&P 500 |
# 374 |
|